Study of the pre and post-synaptic dopaminergic system by DaTSCAN/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients;Estudio pre y postsináptico de la vía nigroestriada mediante DaTSCAN o IBZM SPECT en el diagnóstico diferencial del parkinsonismo en 75 pacientes

Neurologia

Volumn 19, Issue 6, 2004, Pages 292-300

  Vaamonde, Julia ^a,c   Ibanez R ^a   Garcia A M ^b   Poblete, V ^b  

^a Servicios de Neurologia   (Spain)

^b Unidad de Medicina Nuclear   (Spain)

^c Servicio de Neurologia   (Spain)

Author keywords

DaTSCAN IBZM SPECT; Differential diagnosis; Parkinsonism

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GABAPENTIN; IODINE 123; LEVODOPA; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; PERGOLIDE; PRAMIPEXOLE; PRIMIDONE; PROPANOL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC SYSTEM; ESSENTIAL TREMOR; HUMAN; MAJOR CLINICAL STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; POSTSYNAPTIC MEMBRANE; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; BRAIN; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DOPAMINE; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PRESYNAPTIC TERMINALS; PYRROLIDINES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 3342886062     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hoover JE, Strick PL. Multiple output channels in the basal ganglia. Science 1993;259:819-21.
2. Parent A, Hazrati LN. Functional anatomy of the basal ganglia I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Rev 1995;20:91-27.
3. Chesselet MF, Delfs JM. Basal ganglia and movement disorders. Trends Neurosci 1998;19:417-22.
4. Stern MB, Koller WC. Parkinsonian syndromes. New York: Marcel-Dekker Inc, 1993.
5. Zhang ZX, Román GC. Worldwide occurrence of Parkinson's disease: updated review. Neuroepidemiology 1993;12:195-208.
6. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14:317-35.
7. Forno LS. The Lewy body in Parkinson's disease. Adv Neurol 1986;45:35-43.
8. Pascual J, Berciano J, Pazos A. Caracteristicas bioquímicas de la enfermedad de Parkinson y otras causas de parkinsonismo. En: Obeso JA, Tolosa E, Grandas F, editores. Tratado sobre la enfermedad de Parkinson. Madrid: Luzán 5, 1997; p. 155-63.
9. Brooks DJ, Ibánez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with c-raclopride and positron emision tomography. Ann Neurol 1992;31:184-92.
10. Martí-Massó JF, Ruiz Martinez J. Parkinsonismos secundarios. En: Jiménez-Jiménez FJ, Luquin MR, Molina JA, editores. Tratado de los trastornos del movimiento. Madrid: Editorial IM & C, 1998; p. 513-42.
11. Muñoz E, Aguilar M, López del Val J. Otras causas de parkinsonismo. En: Jiménez-Jiménez FJ, Luquin MR, Molina JA, editores. Tratado de los trastornos del movimiento. Madrid: Editorial IM & C 1998; p. 543-64.
12. Findley LJ, Salisachs P. Problems in the differential diagnosis of essential tremor. En: Findley LJ, Capildeo R, editores. Movement disorders: tremor. London: MacMillan, 1984.
13. Hughes A, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
14. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB). Report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
15. Ramos A, Quintana F, Diez C, Leno C, Berciano J. CT findings in spinocerebellar degeneration. Am J Neurosurg Psychiatry 1987;8:635-40.
16. Ormerod IE, Harding A, Miller DH, Jhonson G, MacManus D, Du Boulay EP, et al. Magnetic Resonance imaging in degenerative ataxic disorders. J Neurol Neurosurg Psychiatry 1994;57:51-7.
17. Hughes AJ, Lees A, Stern GM. Apomorphine test to predict dopaminergic response in parkinsonian syndrome. Lancet 1990;336:32-4.
18. Vaamonde J, Ibáñez R, del Real MA, Márquez MD, Gudín MA, Obeso JA. Dyskinesia and segmental motor response in 30 parkinsonian patients during iv apomorphine infusions. Mov Disord 1997;12(Suppl):S123.
19. Booij J, Habraken JBA, Bergman P, Bergmans P, Tissingh G, Winogradzka A, et al. Imaging of dopamine transporters with I-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998;39:1879-84.
20. Booij J, Tissing G, Winogrodzk A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism (review). Eur J Nucl Med 1999;26:171-82.
21. Fhan S, Tolosa E, Marin C. Clinical rating scale for tremor. En: Jankovic J, Tolosa E, editores. Parkinson's disease and movement disorders. Baltimore: Urban and Schwarzenberg, 1988; p. 225-34.
22. Findley LJ, Salisachs P. Problems in the differential diagnosis of essential tremor. En: Findley LJ, Capildeo R, editores. Movement disorders: tremor. London: MacMillan, 1984.
23. Rajput AH, Rozdilsky B, Ang L, Rajput A. Significance of parkinsonian manifestations in essential tremor. Can J Neurol Sci 1993;20:114-7.
24. Lance JW, Schwab RS, Peterson EA. Action tremor and the cog-wheel phenomenon in Parkinson's disease. Brain 1963;86:95-110.
25. Koller WC, Vetere-Overfield B, Barter R. Tremors in early Parkinson's disease. Clin Neuropharmacol 1989;12:293-7.
26. Quinn N. Parkinsonism-recognition and differential diagnosis. Br Med J 1995;310:447-52.
27. Cleeves L, Findley LJ. Variability in amplitude of untreated essential tremor. J Neurol Neurosurg Psychiatry 1987;50:704-8.
28. Benamer HTS, Patterson J, Grosset DG. FP-CIT SPECT in the differential diagnosis of parkinsonism and tremor disorders. En: Wolters ECh, Tolosa E, editores. New tools in the diagnosis of Parkinsonism. Utrecht-The Netherlands: Hoonte Bosch-Keuning, 2001.
29. Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:590-4.
30. Schwab RS, Young RR. Non resting tremor in Parkinson's disease. Trans Am Neurol Assoc 1971;96:305-7.
31. Findley LF, Gresty MA. Supression of rubral tremor with levodopa. Br Med J 1980;281:1428.
32. Ito Y, Fujita M, Shimada S, Watanabe Y, Okada T, Kusuoka H, et al. Comparison between the decrease of dopamine transporter and that of L-Dopa uptake for detection of early to advanced stage of Parkinson's diseasein animal models. Synapse 1999;31:178-85.
33. Brod TM. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989;146:1353.
34. a ed. Baltimore: Williams and Wilkins, 1997; p. 263-95.
35. Ormerod IE, Harding AE, Miller DH, Jhonson G, MacManus D, du Boulay EP, et al. Magnetic resonance imaging in degenerative ataxic disorders. J Neurol Neurosurg Psychiatry 1994;57:51-7.
36. Goetz CG, Tanner CH, Klawans HL. The pharmacology of olivopontocerebellar atrophy. En: Duvoisin RC, Plaitakis A, editores. The olivopontocerebellar atrophy. New York: Raven Press, 1984; p. 143-8.
37. Vaamonde J, Ibáñez R, Gudín MA, Hernández A, De Luis P, Del Real MA. Caídas hacia atrás: signo atípico para una enfermedad de Parkinson idiopática. Utilidad de la apomorfina intravenosa como test diagnóstico. Rev Neurol 2003;31:1147-51.
38. Quinn N. Multiple system atrophy-the nature of the best [review]. J Neurol Neurosurg Psychiatry 1989;52(Suppl);78-89.
39. Burns DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy and Steele-Richardson-Olszewski syndrome: discriminant analysis of F-dopa PET data. J Neurol Neurosurg Psychiatry 1994;57:278-84.
40. Schwarz J, Tatsch K, Arnold G. 123I-iodobenzamide. SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992;42:556-61.
41. Wenning GK, Quinn N, Magalhaes M, Mathias C, Daniel SE. «Minimal change» multisystem atrophy. Mov Disord 1994;9:161-6.
42. Wenning GK, Ben-Sholomo Y, Magalhaes M, Daniel SE, Quinn N. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-6.
43. Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998;44:143-7.
44. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinonovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-40.